Drugs Genetics Nurses 
XTalks
MAY 26, 2023
Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable gene therapy.
STAT News
APRIL 3, 2023
When the long-awaited moment arrived, a nurse helped Adam Hess loosen a tiny plastic clamp on an intravenous line leading to the chest of his son, who lay asleep in a bed at Boston Children’s Hospital.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 25, 2021
The company is best known for its saliva-based health and ancestry DNA testing targeted at consumers, but also uses its genetic database to look for new targets for drug development. The transaction is expected to close before the end of the year.
The Pharma Data
NOVEMBER 26, 2020
26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. About BASE10 Genetics, Inc. SOURCE BASE10 Genetics, Inc. CHICAGO , Nov. About DNA Link, Inc.
XTalks
MAY 12, 2023
Rett syndrome is a rare genetic disorder that predominantly affects girls and leads to severe physical and cognitive impairments. In March, the US Food and Drug Administration (FDA) approved Daybue (trofinetide) , the first and only treatment for Rett syndrome. It affects around one in 10,000 girls born each year. – Dr.
pharmaphorum
FEBRUARY 25, 2021
Chaired by the Genetic Alliance, the virtual meeting saw representatives from Scotland, England, Wales, and Northern Ireland discuss the implementation of the UK Government’s Rare Disease Framework. We now know that 80% of rare diseases have a genetic origin. Genomic technology, therefore, has a key role to play in our work,” he said.
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Side effects and cost implications.
Expert insights. Personalized for you.
87 
Let's personalize your content